- Home
- MRKR vs BOLT Comparison
MRKR vs BOLT Comparison
Compare MRKR & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- BOLT
- Stock Information
- Founded
- MRKR N/A
- BOLT 2015
- Country
- MRKR United States
- BOLT United States
- Employees
- MRKR N/A
- BOLT N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- MRKR Health Care
- BOLT Health Care
- Exchange
- MRKR Nasdaq
- BOLT Nasdaq
- Market Cap
- MRKR 21.9M
- BOLT 22.6M
- IPO Year
- MRKR N/A
- BOLT 2021
- Fundamental
- Price
- MRKR $1.57
- BOLT $0.49
- Analyst Decision
- MRKR Strong Buy
- BOLT Hold
- Analyst Count
- MRKR 1
- BOLT 5
- Target Price
- MRKR $19.00
- BOLT $1.25
- AVG Volume (30 Days)
- MRKR 95.6K
- BOLT 114.3K
- Earning Date
- MRKR 03-25-2025
- BOLT 03-20-2025
- Dividend Yield
- MRKR N/A
- BOLT N/A
- EPS Growth
- MRKR N/A
- BOLT N/A
- EPS
- MRKR N/A
- BOLT N/A
- Revenue
- MRKR $5,395,849.00
- BOLT $9,779,000.00
- Revenue This Year
- MRKR $64.48
- BOLT $9.87
- Revenue Next Year
- MRKR N/A
- BOLT N/A
- P/E Ratio
- MRKR N/A
- BOLT N/A
- Revenue Growth
- MRKR 79.04
- BOLT 35.86
- 52 Week Low
- MRKR $1.48
- BOLT $0.46
- 52 Week High
- MRKR $5.99
- BOLT $1.56
- Technical
- Relative Strength Index (RSI)
- MRKR 35.08
- BOLT 45.52
- Support Level
- MRKR $1.53
- BOLT $0.48
- Resistance Level
- MRKR $1.79
- BOLT $0.52
- Average True Range (ATR)
- MRKR 0.18
- BOLT 0.03
- MACD
- MRKR 0.03
- BOLT 0.00
- Stochastic Oscillator
- MRKR 14.52
- BOLT 40.32
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.